Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) – Pipeline Review, H2 2017’, provides in depth analysis on Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Women's Health, Central Nervous System, Dermatology and Metabolic Disorders under development targeting Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)

The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arvinas Inc

AstraZeneca Plc

Atossa Genetics Inc

Chamaeleo Pharma NV

EndoCeutics Inc

Genentech Inc

H3 Biomedicine Inc

Mithra Pharmaceuticals SA

Novartis AG

Nuevolution AB

Shenogen Pharma Group Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview 8

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 15

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment 17

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development 23

Arvinas Inc 23

AstraZeneca Plc 23

Atossa Genetics Inc 23

Chamaeleo Pharma NV 24

EndoCeutics Inc 24

Genentech Inc 25

H3 Biomedicine Inc 25

Mithra Pharmaceuticals SA 26

Novartis AG 26

Nuevolution AB 27

Shenogen Pharma Group Ltd 27

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles 28

(acolbifene hydrochloride + prasterone) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

(drospirenone + estetrol) - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

acolbifene hydrochloride - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Endoxifen - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Estetrol - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

fosfestrol - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

fulvestrant - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

fulvestrant - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

GDC-0927 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

H-3B6545 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Loseasonique - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

NDC-1308 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Antagonize Estrogen Receptor Alpha for Metastatic Breast Cancer - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

SNG-8023 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

SR-16234 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

sulfestrol - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

TTC-352 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

VP-128 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products 64

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products 66

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones 67

Featured News & Press Releases 67

Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer 67

Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective 67

Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer 68

Aug 18, 2017: Mithra Announces First Subject Completes Estelle Phase III Study 69

Aug 09, 2017: Mithra Pharmaceuticals: Recruitment Completed in Estelle Population PK Substudy 69

Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer 70

Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study 71

Jul 06, 2017: Mithra Strengthens E4 Patent Position in Australian Market 71

Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal 72

Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer 72

Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study 73

Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy 74

May 12, 2017: Mithra to Initiate PK Study for Estelle 74

May 09, 2017: Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study 75

Mar 09, 2017: H3 Biomedicine to Present on H3B-6545 at 2017 American Association of Cancer Research Annual Meeting 75

Appendix 76

Methodology 76

Coverage 76

Secondary Research 76

Primary Research 76

Expert Panel Validation 76

Contact Us 76

Disclaimer 77

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indication, H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Investigation by Universities/Institutes, H2 2017 15

Products under Investigation by Universities/Institutes, H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Stage and Route of Administration, H2 2017 20

Number of Products by Stage and Molecule Type, H2 2017 22

Pipeline by Arvinas Inc, H2 2017 23

Pipeline by AstraZeneca Plc, H2 2017 23

Pipeline by Atossa Genetics Inc, H2 2017 24

Pipeline by Chamaeleo Pharma NV, H2 2017 24

Pipeline by EndoCeutics Inc, H2 2017 25

Pipeline by Genentech Inc, H2 2017 25

Pipeline by H3 Biomedicine Inc, H2 2017 25

Pipeline by Mithra Pharmaceuticals SA, H2 2017 26

Pipeline by Novartis AG, H2 2017 27

Pipeline by Nuevolution AB, H2 2017 27

Pipeline by Shenogen Pharma Group Ltd, H2 2017 27

Dormant Products, H2 2017 64

Dormant Products, H2 2017 (Contd..1), H2 2017 65

Discontinued Products, H2 2017 66

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Routes of Administration, H2 2017 19

Number of Products by Stage and Routes of Administration, H2 2017 19

Number of Products by Molecule Types, H2 2017 21

Number of Products by Stage and Molecule Types, H2 2017 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports